Infliximab biosimilar - Genor BiopharmaAlternative Names: GB 242
Latest Information Update: 04 May 2016
At a glance
- Originator Genor Biopharma
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders